Brief: Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
03/06/2025 21:24
June 3 (Reuters) - AnaptysBio Inc ANAB.O: ANAPTYS ANNOUNCES POSITIVE ROSNILIMAB DATA UPDATED THROUGH SIX MONTHS IN ROBUST PHASE 2B TRIAL IN RA Source text: ID:nGNXH0WLB Further company coverage: ANAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AnaptysBio
See all newsU.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged